Skip to main content
. Author manuscript; available in PMC: 2014 Oct 29.
Published in final edited form as: Influenza Other Respir Viruses. 2014 Feb 7;8(3):347–352. doi: 10.1111/irv.12234

Table 1.

Characteristics of Patients Enrolled and Tested for Respiratory Viruses and Subgroups Positive for Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (HMPV)

Characteristic Total Enrolled and Tested (n = 1248) RSV (n = 32/1248)
2.6%
HMPV (n = 33/1248)
2.6%

Age (yrs), median (25%, 75%) 51.1 (35.3, 65.5) 60.8 (44.8, 68.9) 61 (49.3, 67.3)

Age group, n (%)
 18–49 years 604 (48.4) 12 (37.5) 10 (30.3)
 ≥50 years 644 (51.6) 20 (62.5) 23 (69.7)

Duration of symptoms in days, median (25%, 75%) 3 (1, 5) 4 (2, 6) 3 (2, 4)

Sex, n (%)
 Male 513 (41.1) 11 (34.4) 10 (30.3)
 Female 735 (58.9) 21 (65.6) 23 (69.7)

Race/Ethnicity, n (%)
 White 827 (66.3) 25 (78.1) 23 (69.7)
 Black 386 (30.9) 7 (21.9) 10 (30.3)

Living situation, n (%)
 Lives Alone 231 (18.5) 11 (34.4) 6 (18.2)
 Lives With family 961 (77) 20 (62.5) 27 (81.8)
 In nursing facility 43 (3.5) 1 (3.1) 0 (0)

Chronic illnesses, n (%) 1013 (81.2) 28 (87.5) 29 (87.9)
 Cardiovascular disease 427 (34.2) 15 (46.9) 14 (42.4)
 Pulmonary disease 671 (53.8) 22 (68.8) 21 (63.6)
 Diabetes mellitus 302 (24.2) 7 (21.9) 6 (18.2)
 Immunodeficiency* 680 (54.5) 19 (59.4) 24 (72.7)

Exposure to tobacco smoke**, n (%) 579 (46.4) 16 (50) 11 (33.3)

Abbreviations: HMPV, human metapneumovirus; IQR, interquartile range; RSV, respiratory syncytial virus.

*

Transplant, cancer, splenectomy, HIV/AIDS, steroid use, chemotherapy, hemoglobinopathy, immunosuppression

**

Smoked or had significant environmental tobacco exposure within the last 6 months